Browsing Tag
H.C. Wainwright
4 posts
Ionis Pharmaceuticals (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails, Alnylam Amvuttra and BridgeBio Attruby emerge as clear beneficiaries
Ionis (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails primary endpoint. Peak sales cut to $4B. Alnylam and BridgeBio benefit from the reset.
Uranium Energy Corp (NYSE American: UEC) and the nuclear bet powering the AI grid
AI data centres need power and the US wants domestic nuclear fuel. Uranium Energy Corp (NYSE American: UEC) sits at the centre of both, and it swings hard.
Mirum Pharmaceuticals (NASDAQ: MIRM) jumps 13% after VISTAS Phase 2b PSC win
Two Phase 2b wins in seven days. A pre-NDA meeting this summer. Mirum is starting to look less like a single-product rare disease story.
Positive IDWeek 2025 results highlight Armata’s AP-SA02 phage cocktail as a potential game-changer for Staph bacteremia
Find out how Armata Pharmaceuticals’ AP-SA02 phage therapy could redefine treatment for Staphylococcus aureus bloodstream infections.